MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

2026-02-24 13:50:12 ET

The last time I wrote an article on MoonLake Immunotherapeutics ( MLTX ), it was in a Seeking Alpha article entitled " MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest. " At that time, things were looking very good for the company because it was in the process of running the late-stage VELA program using its drug sonelokimab to treat patients with hidradenitis suppurativa [HS]. Plus, there was a report that Merck ( MRK ) might have made a non-binding offer for the company , valuing it at around $3 billion....

Read the full article on Seeking Alpha

For further details see: